Drugs / Viagenpumatucel-L
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04116710 | Oct 2019 → Aug 2021 | neoplasm | Heat Biologics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02439450 | Apr 2015 → May 2021 | non-small cell lung carcinoma | Heat Biologics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02117024 | Jul 2014 → Dec 2017 | non-small cell lung carcinoma | Heat Biologics | Terminated | No outcome recorded |
| Phase 2 | NCT01504542 | Dec 2011 → Dec 2013 | non-small cell lung carcinoma | Heat Biologics | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | viagenpumatucel-L | “HS-110 (viagenpumatucel-L)” NCT04116710 ↗ |
| Known as | HS-110 | “A Phase 2A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Immune Response, Safety and Efficacy of HS-110 in Combination With Erlotinib vs....” NCT01504542 ↗ |
| Modality | Vaccine | “Immune Response and Safety of HS110 Vaccine” NCT01504542 ↗ |
| Route | Other | “HS-110 administered as 5 intradermal 0.1 mL injections” NCT02439450 ↗ |